DK3712264T5 - Cystathionin-beta-syntaseenzym til behandling af homocystinuri - Google Patents

Cystathionin-beta-syntaseenzym til behandling af homocystinuri Download PDF

Info

Publication number
DK3712264T5
DK3712264T5 DK20168207.7T DK20168207T DK3712264T5 DK 3712264 T5 DK3712264 T5 DK 3712264T5 DK 20168207 T DK20168207 T DK 20168207T DK 3712264 T5 DK3712264 T5 DK 3712264T5
Authority
DK
Denmark
Prior art keywords
homocystinuria
treatment
synthase enzyme
cystathionine beta
beta synthase
Prior art date
Application number
DK20168207.7T
Other languages
Danish (da)
English (en)
Other versions
DK3712264T3 (da
Inventor
Jan P Kraus
Tomas Majtan
Erez Bublil
Original Assignee
Univ Colorado Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Colorado Regents filed Critical Univ Colorado Regents
Application granted granted Critical
Publication of DK3712264T3 publication Critical patent/DK3712264T3/da
Publication of DK3712264T5 publication Critical patent/DK3712264T5/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51Lyases (4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88Lyases (4.)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y402/00Carbon-oxygen lyases (4.2)
    • C12Y402/01Hydro-lyases (4.2.1)
    • C12Y402/01022Cystathionine beta-synthase (4.2.1.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
DK20168207.7T 2013-01-29 2014-01-29 Cystathionin-beta-syntaseenzym til behandling af homocystinuri DK3712264T5 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361758138P 2013-01-29 2013-01-29
US13/803,804 US9034318B2 (en) 2011-08-30 2013-03-14 Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria
EP17172478.4A EP3282013B1 (en) 2013-01-29 2014-01-29 Cystathionine beta-synthase enzyme for treatment of homocystinuria

Publications (2)

Publication Number Publication Date
DK3712264T3 DK3712264T3 (da) 2024-05-06
DK3712264T5 true DK3712264T5 (da) 2024-08-26

Family

ID=51223166

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20168207.7T DK3712264T5 (da) 2013-01-29 2014-01-29 Cystathionin-beta-syntaseenzym til behandling af homocystinuri

Country Status (13)

Country Link
US (4) US9034318B2 (OSRAM)
EP (4) EP3282013B1 (OSRAM)
JP (4) JP6453243B2 (OSRAM)
CN (2) CN105452457A (OSRAM)
AU (3) AU2014212471B2 (OSRAM)
BR (1) BR112015017775A2 (OSRAM)
CA (1) CA2898772A1 (OSRAM)
DK (1) DK3712264T5 (OSRAM)
FI (1) FI3712264T3 (OSRAM)
HK (1) HK1213291A1 (OSRAM)
IL (1) IL239783B (OSRAM)
PT (1) PT3712264T (OSRAM)
WO (1) WO2014120770A1 (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003251550A1 (en) 2002-06-17 2003-12-31 The Regents Of The University Of Colorado HUMAN CYSTATHIONINE Beta-SYNTHASE VARIANTS AND METHODS OF PRODU CTION THEREOF
US9034318B2 (en) * 2011-08-30 2015-05-19 The Regents Of The University Of Colorado, A Body Corporate Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria
US9675678B2 (en) 2013-01-29 2017-06-13 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
HUE066137T2 (hu) 2013-10-18 2024-07-28 Novartis Ag A prosztata-specifikus membrán antigén (PSMA) jelzett inhibitorai, alkalmazásuk képalkotásban és gyógyszerkészítmények prosztatarák kezelésére
HRP20220407T1 (hr) 2015-11-09 2022-05-27 The Regents Of The University Of Colorado, A Body Corporate Pripravci i postupci za uporabu u liječenju homocistinurije
MX2019012347A (es) * 2017-04-17 2020-01-15 Univ Colorado Regents Optimizacion de terapia de reemplazo enzimatico para el tratamiento de la homocistinuria.
US11033612B2 (en) * 2017-05-12 2021-06-15 Board Of Regents, The University Of Texas System Human-enzyme mediated depletion of homocysteine for treating patients with hyperhomocysteinemia and homocystinuria
US20190309271A1 (en) 2018-03-20 2019-10-10 Rubius Therapeutics, Inc. Therapeutic cell systems and methods for treating homocystinuria
CN108795913B (zh) * 2018-05-04 2021-07-02 山西大学 一种植物中能催化h2s产生的酶及其应用
AR116866A1 (es) 2018-10-26 2021-06-23 Univ Texas Enzimas de degradación de cistina / cisteína de primates modificadas por ingeniería genética
FI3990005T3 (fi) 2019-06-26 2025-11-28 Travere Therapeutics Switzerland Gmbh Pegyloitu kystationiini-beta-syntaasi entsyymihoitoa varten homokystinurian hoitamiseksi
CN114630673A (zh) * 2019-09-03 2022-06-14 特拉维尔治疗瑞士有限公司 用于治疗升高的同型半胱氨酸水平的胱硫醚β-合成酶酶疗法
USD1013704S1 (en) * 2021-07-09 2024-02-06 The Regents Of The University Of Colorado, A Body Corporate Display screen or portion thereof with graphical user interface
USD1014518S1 (en) * 2021-07-09 2024-02-13 The Regents Of The University Of Colorado, A Body Corporate Display screen or portion thereof with graphical user interface
CN115721735A (zh) * 2022-10-13 2023-03-03 呈诺再生医学科技(北京)有限公司 Cbs基因在制备糖尿病视网膜病变治疗药物中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57209206A (en) 1981-06-08 1982-12-22 Kanebo Ltd Skin type pack agent
US5523225A (en) 1993-09-13 1996-06-04 Regents Of The University Of Colorado DNA sequence encoding human cystathionine β-synthase
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5730990A (en) 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5635375A (en) 1995-01-09 1997-06-03 Regents Of The University Of Colorado Method of increasing the yield and heme saturation of cystathione β-synthase
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US6635438B2 (en) * 1999-11-02 2003-10-21 Catch, Inc. Enzymatic cycling assays for homocysteine and cystathionine
AU2003251550A1 (en) * 2002-06-17 2003-12-31 The Regents Of The University Of Colorado HUMAN CYSTATHIONINE Beta-SYNTHASE VARIANTS AND METHODS OF PRODU CTION THEREOF
EP1396537A1 (en) 2002-09-04 2004-03-10 Avidis SA Treatment of elevated plasma homocysteine
CN101322840A (zh) * 2008-05-28 2008-12-17 中国人民解放军军事医学科学院卫生学环境医学研究所 一种人胱硫醚β-合成酶重组蛋白及应用
BR112013000027A2 (pt) 2010-07-01 2017-07-11 Isis Innovation tratamento de distúrbios cognitivos
US9034318B2 (en) 2011-08-30 2015-05-19 The Regents Of The University Of Colorado, A Body Corporate Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria
US9243239B2 (en) 2012-03-26 2016-01-26 The Regents Of The University Of Colorado, A Body Corporate Purification of cystathionine beta-synthase
US9675678B2 (en) * 2013-01-29 2017-06-13 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria

Also Published As

Publication number Publication date
IL239783A0 (en) 2015-08-31
JP2021000142A (ja) 2021-01-07
US9034318B2 (en) 2015-05-19
AU2014212471A8 (en) 2015-08-13
US20150344864A1 (en) 2015-12-03
IL239783B (en) 2019-10-31
HK1249137A1 (en) 2018-10-26
FI3712264T3 (fi) 2024-05-07
JP2023062201A (ja) 2023-05-02
JP2016506727A (ja) 2016-03-07
EP4406536A3 (en) 2025-01-01
AU2014212471A1 (en) 2015-07-23
CN112574982B (zh) 2025-05-13
CA2898772A1 (en) 2014-08-07
CN105452457A (zh) 2016-03-30
JP7240743B2 (ja) 2023-03-16
EP4406536A2 (en) 2024-07-31
EP3712264A8 (en) 2020-11-04
AU2020200719A1 (en) 2020-02-20
EP2951299A1 (en) 2015-12-09
US20140212403A1 (en) 2014-07-31
US20170065687A1 (en) 2017-03-09
EP3712264A1 (en) 2020-09-23
US9447406B2 (en) 2016-09-20
JP6453243B2 (ja) 2019-01-16
AU2014212471B2 (en) 2019-11-28
JP7580822B2 (ja) 2024-11-12
AU2022263598B2 (en) 2025-06-05
US10046036B2 (en) 2018-08-14
EP2951299B1 (en) 2017-07-12
US20180311325A1 (en) 2018-11-01
HK1213291A1 (zh) 2016-06-30
WO2014120770A1 (en) 2014-08-07
CN112574982A (zh) 2021-03-30
JP2019059768A (ja) 2019-04-18
EP3712264B1 (en) 2024-04-10
PT3712264T (pt) 2024-05-09
DK3712264T3 (da) 2024-05-06
BR112015017775A2 (pt) 2017-11-21
US10624959B2 (en) 2020-04-21
AU2022263598A1 (en) 2022-12-15
EP3282013A1 (en) 2018-02-14
EP3282013B1 (en) 2020-05-20
AU2020200719B2 (en) 2022-08-18

Similar Documents

Publication Publication Date Title
DK3712264T5 (da) Cystathionin-beta-syntaseenzym til behandling af homocystinuri
IL268340A (en) Glucosylceramide synthase inhibitors for the treatment of diseases
DK3362461T3 (da) Mrna-cap-analoger med modificeret phosphatbinding
EP2990700A4 (en) SLIDING PART
DK3027742T3 (da) Enzymvarianter
DK2971167T3 (da) Sammensætninger og fremgangsmåder til targeting af nucleinsyre med nucleinsyrer
DK3033086T3 (da) Kombinationsterapi til behandling af cancer
DK3004666T3 (da) Skrue
EP2889350A4 (en) ADHESIVE COMPOSITION
EP2967969C0 (en) IMPLANT
PL3083764T3 (pl) Sieciowane przez kondensację silikony mające stabilność temperaturową
GB201313905D0 (en) Fixing
DK3027750T3 (da) Biokatalytisk sammensætning
PT3340966T (pt) Composições de insulina de ação rápida
DK3010895T3 (da) Fremgangsmåde til fremstilling af 4-propargyleret aminobenzoxazinoner
DK3021839T3 (da) Sammensætninger for behandling af fibrose
LT3563837T (lt) Terapija bakteriofagu
DK3511004T3 (da) Kombineret præparat til behandling af cancer
FR3014969B1 (fr) Fixation temporaire
DK3052102T3 (da) Sammensætninger til behandling af cancere
EP3369947A4 (en) FASTENERS
DK2986325T3 (da) Fremgangsmåder til behandling af forstyrrelser i urinstofcyklus
DK3154908T3 (da) Fremgangsmåde til fremstilling af gel med høj dispergerbarhed
EP3060191C0 (en) A dispenser
EP3293586A4 (en) CLOCK